share_log

Moderna | DEFA14A: Others

Moderna | DEFA14A: Others

Moderna | DEFA14A:其他
SEC announcement ·  03/21 08:51
Moomoo AI 已提取核心信息
Moderna, Inc. has filed a definitive proxy statement with the United States Securities and Exchange Commission (SEC). This filing is in accordance with Section 14(a) of the Securities Exchange Act of 1934, indicating that Moderna is preparing for upcoming corporate actions that require shareholder approval. The definitive proxy statement is a key document that outlines the agenda for the company's shareholder meeting, including matters such as election of directors, approval of compensation plans, and other significant corporate decisions. The document confirms that no filing fee is required for this submission.
Moderna, Inc. has filed a definitive proxy statement with the United States Securities and Exchange Commission (SEC). This filing is in accordance with Section 14(a) of the Securities Exchange Act of 1934, indicating that Moderna is preparing for upcoming corporate actions that require shareholder approval. The definitive proxy statement is a key document that outlines the agenda for the company's shareholder meeting, including matters such as election of directors, approval of compensation plans, and other significant corporate decisions. The document confirms that no filing fee is required for this submission.
Moderna, Inc. 已向美国证券交易委员会(SEC)提交了最终委托书。该文件符合1934年《证券交易法》第14(a)条,表明Moderna正在为即将到来的需要股东批准的公司行动做准备。最终委托书是一份重要文件,概述了公司股东大会的议程,包括董事选举、薪酬计划的批准和其他重大公司决策等事项。该文件确认本次提交不需要任何申请费。
Moderna, Inc. 已向美国证券交易委员会(SEC)提交了最终委托书。该文件符合1934年《证券交易法》第14(a)条,表明Moderna正在为即将到来的需要股东批准的公司行动做准备。最终委托书是一份重要文件,概述了公司股东大会的议程,包括董事选举、薪酬计划的批准和其他重大公司决策等事项。该文件确认本次提交不需要任何申请费。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息